China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a Phase I/IIa trial of its CD73 monoclonal antibody (mAb), JAB-BX102, for advanced solid tumors. The study, cleared by Chinese regulators in March 2022, marks the drug’s global clinical debut after U.S. approval in October 2021.
Study Design
The multi-center, open-label trial evaluates JAB-BX102’s safety, pharmacokinetics, and anti-tumor activity when combined with pembrolizumab in adults with advanced solid tumors. The regimen targets CD73, a key enzyme in tumor immune evasion, aiming to enhance checkpoint inhibitor efficacy.
Preclinical Data
Preclinical studies showed JAB-BX102’s dose-dependent activity and potential to inhibit tumor growth. The drug’s U.S. Phase I/IIa approval in 2021 made it Jacobio’s first macro molecule in overseas trials, highlighting its global pipeline ambitions.
Strategic Significance
CD73 is a novel oncology target, with no approved therapies globally. Jacobio’s program joins Eli Lilly’s LY-3475070, BMS’s BMS-986179, and others in early-stage development. The company plans to leverage JAB-BX102’s dual mechanisms—blocking adenosine signaling and enhancing PD-(L)1 inhibitor synergy—to address unmet needs in solid tumors.-Fineline Info & Tech
